Thumbnail
Access Restriction
Open

Author Di Iorio, Giuseppe ♦ Baroni, Gaia ♦ Lorusso, Marco ♦ Montemitro, Chiara ♦ Spano, Maria Chiara ♦ di Giannantonio, Massimo
Editor Herrera-Marschitz, Mario
Source Hindawi
Content type Text
Publisher Hindawi
File Format PDF
Copyright Year ©2017
Language English
Abstract Several evidences support the hypothesis that glutamatergic dysfunction may be implicated in the pathogenesis of schizophrenia and in the last few years great interest has been focused on the role of the N-methyl-D-aspartate receptor (NMDAR). Glutamate is the main excitatory neurotransmitter in human CNS and it plays a prominent role in synaptic plasticity, learning, and memory and other cognitive functions. Increasing interest in memantine add-on therapy in schizophrenic patients with negative and cognitive symptoms may suggest that memantine could be a new promising treatment in schizophrenia. The aim of this update was to evaluate clinical data about the memantine effectiveness in schizophrenic patients. Our systematic review of the literature highlights that memantine therapy in schizophrenic patients seems to improve mainly negative symptoms while positive symptoms and cognitive symptoms did not improve significantly.
ISSN 20900104
Learning Resource Type Article
Publisher Date 2017-01-24
Rights License This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
e-ISSN 20900112
Journal Journal of Amino Acids
Volume Number 2017
Page Count 6


Open content in new tab

   Open content in new tab